Research Analysts Set Expectations for PBLS FY2026 Earnings

Parabilis Medicines, Inc. (NASDAQ:PBLS – Free Report) – HC Wainwright lowered their FY2026 earnings estimates for Parabilis Medicines in a report issued on Friday, November 13th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($2.12) per share for the year, down from their previous estimate of ($2.10). HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Parabilis Medicines’ current full-year earnings is ($2.56) per share. HC Wainwright also issued estimates for Parabilis Medicines’ Q4 2026 earnings at ($0.37) EPS, Q1 2027 earnings at ($0.39) EPS, Q2 2027 earnings at ($0.40) EPS, Q3 2027 earnings at ($0.42) EPS, Q4 2027 earnings at ($0.44) EPS and FY2027 earnings at ($1.66) EPS.

A number of other research analysts have also weighed in on the company. Weiss Ratings upgraded Parabilis Medicines from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday. Canaccord Genuity Group started coverage on Parabilis Medicines in a report on Monday, November 9th. They issued a “buy” rating and a $39.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Parabilis Medicines presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.80.

View Our Latest Analysis on Parabilis Medicines

Parabilis Medicines Stock Performance

Shares of PBLS stock opened at $28.47 on Tuesday. Parabilis Medicines has a 52 week low of $22.66 and a 52 week high of $42.49. The business has a fifty day moving average of $30.19.

Parabilis Medicines (NASDAQ:PBLS – Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.04. The company had revenue of $2.11 million for the quarter.

Hedge Funds Weigh In On Parabilis Medicines

Several institutional investors have recently bought and sold shares of PBLS. Alphabet Inc. purchased a new position in shares of Parabilis Medicines in the 2nd quarter worth $134,647,000. General Catalyst Group Management LLC bought a new stake in shares of Parabilis Medicines in the 2nd quarter worth about $43,818,000. WINTON GROUP Ltd purchased a new stake in shares of Parabilis Medicines during the 2nd quarter valued at about $955,000. Squarepoint Ops LLC purchased a new stake in shares of Parabilis Medicines during the 2nd quarter valued at about $1,327,000. Finally, ICONIQ Capital LLC purchased a new stake in shares of Parabilis Medicines during the 2nd quarter valued at about $9,580,000.

About Parabilis Medicines

(Get Free Report)

Parabilis Medicines is a clinical-stage biopharmaceutical company developing medicines for diseases driven by proteins that have been difficult to target with conventional drugs. Its research focuses on macrocyclic peptides designed to address challenging protein interactions, including targets relevant to cancer. The company uses its proprietary Helicon platform to design these peptide-based drug candidates. Parabilis is based in Cambridge, Massachusetts, and was formerly known as Peptone. Parabilis was founded by Gregory Verdine, who serves as the company’s chief executive officer.

Read More

Earnings History and Estimates for Parabilis Medicines (NASDAQ:PBLS)

Receive News & Ratings for Parabilis Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parabilis Medicines and related companies with MarketBeat.com's FREE daily email newsletter.